Ocular Therapeutix, Inc. (NASDAQ:OCUL) Insider Donald Notman Sells 11,119 Shares

Ocular Therapeutix, Inc. (NASDAQ:OCUL) insider Donald Notman sold 11,119 shares of Ocular Therapeutix stock in a transaction on Tuesday, February 4th. The shares were sold at an average price of $7.81, for a total value of $86,839.39. Following the sale, the insider now directly owns 193,444 shares of the company’s stock, valued at $1,510,797.64. This represents a 5.44 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Donald Notman also recently made the following trade(s):

• On Friday, January 31st, Donald Notman sold 6,301 shares of Ocular Therapeutix stock. The shares were sold at an average price of $7.84, for a total value of $49,399.84.

Ocular Therapeutix Trading Up 3.6 %

OCUL traded up $0.27 during trading on Tuesday, hitting $7.82. 904,622 shares of the stock traded hands, compared to its average volume of 904,992. The firm has a market capitalization of $1.23 billion, a P/E ratio of -5.92 and a beta of 1.22. Ocular Therapeutix, Inc. has a 12-month low of $4.06 and a 12-month high of $11.77. The company has a debt-to-equity ratio of 0.19, a current ratio of 13.01 and a quick ratio of 12.94. The firm has a 50-day moving average of $8.61 and a 200 day moving average of $9.02.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on OCUL. HC Wainwright reaffirmed a “buy” rating and issued a $15.00 target price on shares of Ocular Therapeutix in a research note on Tuesday, December 3rd. Scotiabank started coverage on shares of Ocular Therapeutix in a research note on Wednesday, October 16th. They issued a “sector outperform” rating and a $22.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and six have given a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $16.71.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. Mirae Asset Global Investments Co. Ltd. increased its position in Ocular Therapeutix by 22.0% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,639 shares of the biopharmaceutical company’s stock valued at $49,000 after purchasing an additional 1,015 shares during the period. Capital Performance Advisors LLP bought a new position in Ocular Therapeutix in the third quarter worth about $70,000. Algert Global LLC purchased a new stake in Ocular Therapeutix in the second quarter worth about $69,000. Palumbo Wealth Management LLC purchased a new position in shares of Ocular Therapeutix during the 4th quarter worth approximately $100,000. Finally, Diversified Trust Co bought a new position in shares of Ocular Therapeutix in the 3rd quarter worth approximately $106,000. Hedge funds and other institutional investors own 59.21% of the company’s stock.

About Ocular Therapeutix

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.